Lilly Partners UK Immunometabolism Biotech in Deal Worth €811M
Eli Lilly will partner Oxford-based Sitryx to develop up to four drug candidates to treat…
Eli Lilly will partner Oxford-based Sitryx to develop up to four drug candidates to treat…
A deal between Swiss biotech AC Immune and Eli Lilly to develop an oral Alzheimer’s…
Update (30/09/2019): A long legal battle between Adocia and Eli Lilly over a fast-acting insulin…
AC Immune will receive €27.6M (CHF 30M) from big pharma Eli Lilly as it begins…
In the midst of a legal litigation with Eli Lilly, Adocia has released Phase 1…
Novo Nordisk has positive Phase III trial results for its oral version of semaglutide, a…
Update (13/02/2018): The European Commission has given Novo Nordisk a market authorization for Ozempic (semaglutide), bringing…
CureVac will be working with pharma giant Eli Lilly in the development of up to…
Topas Therapeutics has signed a multi-year agreement with Eli Lilly to develop drug candidates for…
Novo Nordisk has reported Phase III data that reveal its candidate semaglutide improved glucose control…
Probiodrug has disclosed encouraging results of its latest Phase IIa trial to assess its lead…
Eli Lilly has decided to terminate its partnership with Adocia for the development of BioChaperone…